Contract development and manufacturing organization eXmoor Pharma signed a strategic collaboration with University College London’s Translational Research Office to accelerate academic cell and gene therapy (CGT) projects toward clinical readiness. The partnership will provide early CMC consulting, analytical development, GMP manufacturing and regulatory strategy support for UCL innovators. The program aims to reduce translational friction by engaging eXmoor’s multidisciplinary teams early, offering grant input, consultancy clinics, and shared labs to shape scalable development approaches. eXmoor expects to gain early insight into emergent modalities while UCL gains pathways to GMP readiness. By formalizing academia‑industry handoffs, the collaboration seeks to shorten timelines to IND/CTA filings and de‑risk early CGT programs — a model that could be replicated at other translational hubs.